参考文献/References:
[1]Melak T,Baynes HW. Circulating microRNAs as possible biomarkers for coronary artery disease:a narrative review[J]. EJIFCC,2019,30(2):179-194.
[2]Su M,Niu Y,Dang Q,et al. Circulating microRNA profiles based on direct S-Poly(T)Plus assay for detection of coronary heart disease[J]. J Cell Mol Med,2020, 24(11):5984-5997.
[3]Zhang L,Zhang Y,Zhao Y,et al. Circulating miRNAs as biomarkers for early diagnosis of coronary artery disease[J]. Expert Opin Ther Pat,2018,28(8):591-601.
[4]Zhang Y,Zhang L,Wang Y,et al. MicroRNAs or long noncoding RNAs in diagnosis and prognosis of coronary artery disease[J]. Aging Dis,2019,10(2):353-366.
[5]Parizadeh SM,Ferns GA,Ghandehari M,et al. The diagnostic and prognostic value of circulating microRNAs in coronary artery disease:a novel approach to disease diagnosis of stable CAD and acute coronary syndrome[J]. J Cell Physiol, 2018,233(9):6418-6424.
[6]GBD 2016 Causes of Death Collaborators. Global,regional,and national age-sex specific mortality for 264 causes of death,1980-2016:a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet,2017,390(10100):1151-1210.
[7]van Meter EN,Onyango JA,Teske KA. A review of currently identified small molecule modulators of microRNA function[J]. Eur J Med Chem,2020,188:112008.
[8]Carthew RW,Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs[J]. Cell,2009,136(4):642-655.
[9]Valinezhad Orang A,Safaralizadeh R,Kazemzadeh-Bavili M. Mechanisms of miRNA-Mediated Gene Regulation from Common Downregulation to mRNA-Specific Upregulation[J]. Int J Genomics,2014,2014:970607.
[10]Ha M,Kim VN. Regulation of microRNA biogenesis[J]. Nat Rev Mol Cell Biol,2014,15(8):509-524.
[11]Saliminejad K,Khorram Khorshid HR,Soleymani Fard S,et al. An overview of microRNAs:biology,functions,therapeutics,and analysis methods[J]. J Cell Physiol,2019,234(5):5451-5465.
[12]Mori MA,Ludwig RG,Garcia-Martin R,et al. Extracellular miRNAs:from biomarkers to mediators of physiology and disease[J]. Cell Metab,2019,30(4):656-673.
[13]Sabre L,Punga T,Punga AR. Circulating miRNAs as potential biomarkers in myasthenia gravis:tools for personalized medicine[J]. Front Immunol,2020,11:213.
[14]Doxakis E. Cell-free microRNAs in Parkinson’s disease:potential biomarkers that provide new insights into disease pathogenesis[J]. Ageing Res Rev,2020,58:101023.
[15]Kaudewitz D,Zampetaki A,Mayr M. MicroRNA biomarkers for coronary artery disease?[J]. Curr Atheroscler Rep,2015,17(12):70.
[16]Kumar D,Narang R,Sreenivas V,et al. Circulatory miR-133b and miR-21 as novel biomarkers in early prediction and diagnosis of coronary artery disease[J]. Genes (Basel),2020,11(2):164.
[17]Zhu L,Chen T,Ye W,et al. Circulating miR-182-5p and miR-5187-5p as biomarkers for the diagnosis of unprotected left main coronary artery disease[J]. J Thorac Dis,2019,11(5):1799-1808.
[18]Li H,Zhang P,Li F,et al. Plasma miR-22-5p,miR-132-5p,and miR-150-3p are associated with acute myocardial infarction[J]. Biomed Res Int,2019,2019:5012648.
[19]Bialek S,Gorko D,Zajkowska A,et al. Release kinetics of circulating miRNA-208a in the early phase of myocardial infarction[J]. Kardiol pol,2015,73(8):613-619.
[20]Bukauskas T,Mickus R,Cereskevicius D,et al. Value of Serum miR-23a,miR-30d,and miR-146a Biomarkers in ST-elevation myocardial infarction[J]. Med Sci Monit, 2019,25:3925-3932.
[21]Zhong Z,Zhong W,Zhang Q,et al. Circulating microRNA expression profiling and bioinformatics analysis of patients with coronary artery disease by RNA sequencing[J]. J Clin Lab Anal,2020,34(1):e23020.
[22]Horvath M,Horvathova V,Hajek P,et al. MicroRNA-331 and microRNA-151-3p as biomarkers in patients with ST-segment elevation myocardial infarction[J]. Sci Rep, 2020,10(1):5845.
[23]Nariman-Saleh-Fam Z,Vahed SZ,Aghaee-Bakhtiari SH,et al. Expression pattern of miR-21, miR-25 and PTEN in peripheral blood mononuclear cells of patients with significant or insignificant coronary stenosis[J]. Gene,2019,698:170-178.
[24]Zhang X,Cai H,Zhu M,et al. Circulating microRNAs as biomarkers for severe coronary artery disease[J]. Medicine (Baltimore),2020,99(17):e19971.
[25]Zhang L,Zhang Y,Xue S,et al. Clinical significance of circulating microRNAs as diagnostic biomarkers for coronary artery disease[J]. J Cell Mol Med, 2020,24(1):1146-1150.
[26]Wang W,Li T,Gao L,et al. Plasma miR-208b and miR-499:potential biomarkers for severity of coronary artery disease[J]. Dis Markers,2019,2019:9842427.
[27]Verma B,Katyal D,Patel A,et al. Relation of systolic and diastolic epicardial adipose tissue thickness with presence and severity of coronary artery disease (The EAT CAD study)[J]. J Family Med Prim Care,2019,8(4):1470-1475.
[28]Coban N,Pirim D,Erkan AF,et al. Hsa-miR-584-5p as a novel candidate biomarker in Turkish men with severe coronary artery disease[J]. Mol Biol Rep,2020, 47(2):1361-1369.
[29]Li H,Gao F,Wang X,et al. Circulating microRNA-378 levels serve as a novel biomarker for assessing the severity of coronary stenosis in patients with coronary artery disease[J]. Biosci Rep,2019,39(5):BSR20182016.
[30]Guo JF,Zhang Y,Zheng QX,et al. Association between elevated plasma microRNA-223 content and severity of coronary heart disease[J]. Scand J Clin Lab Invest,2018,78(5):373-378.
[31]Qiu XK,Ma J. Alteration in microRNA-155 level correspond to severity of coronary heart disease[J].Scand J Clin Lab Invest,2018,78(3):219-223.
[32]Schulte C,Molz S,Appelbaum S,et al. miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease[J]. PLoS One,2015,10(12):e0145930.
[33]Mayer O Jr,Seidlerová J,?erná V,et al. The low expression of circulating microRNA-19a represents an additional mortality risk in stable patients with vascular disease[J]. Int J Cardiol,2019,289:101-106.
[34]Wang X,Dong Y,Fang T,et al. Circulating microRNA-423-3p improves the prediction of coronary artery disease in a general population- six-year follow-up results from the China-Cardiovascular Disease Study[J]. Circ J,2020 ,84(7):1155-1162.
[35]He W,Zhu L,Huang Y,et al. The relationship of microRNA-21 and plaque stability in acute coronary syndrome[J]. Medicine (Baltimore),2019,98(47):e18049.
[36]Tang QJ,Lei HP,Wu H,et al. Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy[J]. Acta Pharmacol Sin,2019,40(2):208-215.
[37]Kim JS,Pak K,Goh TS,et al. Prognostic value of microRNAs in coronary artery diseases:a meta-analysis[J]. Yonsei Med J,2018,59(4):495-500.
[38]Dai R,Liu Y,Zhou Y,et al. Potential of circulating pro-angiogenic microRNA expressions as biomarkers for rapid angiographic stenotic progression and restenosis risks in coronary artery disease patients underwent percutaneous coronary intervention[J]. J Clin Lab Anal,2020,34(1):e23013.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(2):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(2):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(2):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(2):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(2):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(2):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(2):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(2):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]